NewsFox 13 News (WTVT) — All NewsAugust 27, 2026Hillsborough
FDA approves Rasonque for advanced pancreatic cancer treatment
The FDA has granted expedited approval to the drug daraxonrasib, marketed as Rasonque, for patients with advanced pancreatic cancer whose disease has progressed despite prior treatment. Clinical trials showed the daily pill nearly doubled median survival time compared to chemotherapy, extending life to 13.2 months from 6.7 months.
Read the full story at Fox 13 News (WTVT) — All NewsWhy It Matters
Patients with advanced pancreatic cancer now have access to a new treatment option that targets specific genetic mutations, with a one-month supply priced at approximately $39,800.
Key Facts
Each fact below is taken from the article. Click one to see the exact passage.
Who's Mentioned
personAndrew Coveler“Doctor at Fred Hutch Cancer Center who commented on the significance of the appr”organizationFood and Drug Administration“Granted expedited approval for the new drug.”personBen Sasse“Former Senator who publicly stated he experienced reduced pain while taking the ”organizationFred Hutch Cancer Center“Affiliation of Dr. Andrew Coveler.”organizationRevolution Medicines“Manufacturer of the drug Rasonque.”organizationAmerican Cancer Society“Provided statistics on pancreatic cancer diagnosis and mortality rates.”